



Idera to Present at the 22nd Annual NewsMakers in the Biotech Industry Conference

September 4, 2015 4:01 PM EDT

CAMBRIDGE, Mass. and EXTON, Pa., Sept. 4, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Vincent Milano, Idera's Chief Executive Officer will present a corporate update at the 22nd Annual NewsMakers in the Biotech Industry Conference on Thursday, September 10, 2015 at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York City.

Live audio webcasts of Idera's presentations will be accessible in the Investors and Media section of Idera's website at <http://www.iderapharma.com>. Archived versions will also be available on the Company's website after the event for 90 days.

About Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera's proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera is developing a third generation antisense technology platform that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.

CONTACT: Investor and Media Contact
Robert Doody
VP, IR & Corporate Communications
617-679-5515 (office)
484-639-7235 (mobile)
rdooddy@iderapharma.com

[Idera Pharmaceuticals Logo](#)

Idera Pharmaceuticals